Drug Profile
Research programme: inflammatory diseases - Celtaxsys
Latest Information Update: 28 Jan 2020
Price :
$50
*
At a glance
- Originator Celtaxsys
- Class Anti-inflammatories
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cystic fibrosis; Eosinophilic oesophagitis; Hidradenitis suppurativa; Pulmonary arterial hypertension
Most Recent Events
- 28 Jan 2020 No recent reports of development identified for research development in Cystic-fibrosis in USA
- 28 Jan 2020 No recent reports of development identified for research development in Eosinophilic-oesophagitis in USA
- 28 Jan 2020 No recent reports of development identified for research development in Hidradenitis suppurativa in USA